Stock Price Quote

FRESENIUS KABI ONCOLOGY LTD.

NSE : NABSE : 532545ISIN CODE : INE575G01010Industry : Pharmaceuticals & DrugsHouse : Fresenius Kabi Oncology - MNC
BSE132.450 (0 %)
PREV CLOSE ( ) 132.45
OPEN PRICE ( ) 132.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 132.45 (20430)
VOLUME 91518
TODAY'S LOW / HIGH ( )132.00 132.60
52 WK LOW / HIGH ( ) 132132.6
NSE
This Company is not listed in NSE
BSE NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 18-03 2003
Management Info
Maria Gobbi - Chairman Arvind Kumar Sharma - Managing Director
Registered Office

Address B - 310,Som Datt Chambers - I,Bhikaji Cama Place ,
New Delhi,
Delhi-110066

Phone 011-26105570

Email complianceofficer.india@fresenius-kabi.com

Website www.fresenius-kabi-oncology.com

Registrars Details
Link Intime India Pvt Ltd.
Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi
 Listing : BSE, NSE, MCX

NEWS

12Dec Fresenius Kabi Oncology informs about
Fresenius Kabi Oncology has informed that Dr. Patricia Grigoleit, Non -..
25Jul USFDA issues warning letter to Freseni
US health regulator has issued a warning letter to Fresenius Kabi Oncolo..
23Jul FIPB to take up Fresenius Kabi's propo
The Foreign Investment Promotion Board (FIPB) will consider the proposal..
23Jul Fresenius Kabi gets SEBI’s nod to deli
Fresenius Kabi Oncology has received approval from Securities and Exchan..
23Jul Fresenius Kabi climbs on getting SEBI’
Fresenius Kabi is currently trading at Rs. 128.00, up by 17.60 points or..
MORE

Financials

in Millions
QTR Dec 13 ANNUAL 13
Net Profit-636.27805.89
Gross Profit -488.01 1216.19
Operating Profit -385.641474.05
Net Sales 846.625963
MORE

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Fredun Pharma (BSE)
peergroup  827.60 (8.15%)
M.Cap ( in Cr)391.87
Mankind Pharma (BSE)
peergroup  2393.90 (2.40%)
M.Cap ( in Cr)95606.44
Torrent Pharma (BSE)
peergroup  2636.30 (1.76%)
M.Cap ( in Cr)89117.76
Ajanta Pharma (BSE)
peergroup  2135.80 (2.17%)
M.Cap ( in Cr)26861.59
Strides Pharma Scien (BSE)
peergroup  890.20 (5.24%)
M.Cap ( in Cr)8180.91
MORE

Shareholding Pattern

PROMOTERS 0%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%
NON-INSTITUTION 0%
MORE

About Fresenius Kabi Oncology Ltd.

Fresenius Kabi Oncology Ltd. was incorporated in the year 2003. Its today's share price is 132.45. Its current market capitalisation stands at Rs 2254.93 Cr. In the latest quarter, company has reported Gross Sales of Rs. 6595.68 Cr and Total Income of Rs.7014.5 Cr. The company's management includes Uday Chandrashekhar Shetty, Rakesh Bhargava, Rajiv Lochan Jain, Karsten Peter Lerch, Steffen Georg Roser, Michael Schoenhofen, Nikhil Kulshreshtha, Arvind Kumar Sharma, Maria Gobbi.

It is listed on the BSE with a BSE Code of 532545 , NSE with an NSE Symbol of FKONCO and ISIN of INE575G01010. It's Registered office is at B - 310,Som Datt Chambers - I,Bhikaji Cama Place New Delhi-110066, Delhi. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are G Basu & Co, VMT & Co LLP

download beyond app
download beyond app
About Nirmal Bang About Nirmal Bang Awards & Accolades Careers at Nirmal Bang Contact Nirmal BangContact Dp Support Contact Trading Support
Product & Services Equity & Derivatives Trading Forex Trading Commodity Trading Institutional Broking Depository Services Loan Against Securities (LAS) Algo Trading
Equity Price Analysis Volume Analysis Index Analysis News Analysis Corporate Action India Market Other Market Share Market Holidays T+1 Settlement securities
Derivatives Updates Market Report Overview
IPO IPO Issues Performance News & Analysis
Commodities Market Movers News & Commentary MCX / NCDEX HolidaysMCX Data feed product and Charges
Portfolio Management Service (PMS) NBSPL - PMS Disclosure Nirmal Bang PMS - Investor Charter SCORES complaints – March 2024
Mutual Funds About Nirmal Bang Niveshalaya Why Associate with Nirmal Bang Mutual Fund Login Mutual Fund Register FAQs Mutual Fund Holidays SIP Calculator Mutual Funds Updates Mutual Funds Trends Mutual Fund Reports Mutual Fund Terms & Conditions Mutual Privacy Policy
NPS NPS Forms and Guidelines NPS-AML Policy
Nirmal Bang Research Technical Calls Equity Reports Commodity Reports Currency Research Institutional Research
Nirmal Bang Media Knowledge Center Blog Support Center Become A Partner Beyond Market Careers Sitemap Do's And Dont'sInvestor Complaint Data
Other Links Disclaimer Privacy Policy Terms Of Use Rules & Regulations Disclosures Risk Disclosure Grievances NPS Grievance Policy SEBI ScoresRMS Policy Inspection CSR Committee CSR Policy
CSR Activities
FY-2020-2021 FY-2021-2022 FY-2022-2023
Investor Charter
Linked content_Investor Charter for Depositories and DPs Investor Charter for Depositories and DPs Investor Charter for Stock Broker Investor Charter for Research Investor Complaints -RA Investor Complaints-NBEPL
Evoting
NSDL Evoting CDSL Evoting
Client Bank Account list Smartodr Login Investor Grievance Flow Registered AP’sSurrendered List of AP’sKYC Activation Process
Connect with Us
ATTENTION INVESTORS Depository IPO KYC Investor Guide
Inactive account treatmentNBSPL Policy of AMLNBEPL Policy of AMLNBSPL CSR Policy Physical Settlement Policy of Derivative Aadhar UpdationNirmalbang Privacy Policy V1.0 Documents in Vernacular Languages NBSPL PMS Disclosure Document
Nirmal Bang Securities Pvt. Ltd. : Member NSE – ID 09391, SEBI Registration No. NSE CM Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE FO Segment INZ000202536, Member NSE – ID 09391, SEBI Registration No. NSE CDS Segment INZ000202536, Member NSE Commodity – ID 09391, SEBI Registration No. NSE COMMODITY Segment Exchange Registered Broker, Member MSEI – ID 1067, SEBI Registration No. MSEI CM Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI FO Segment INZ000202536, Member MSEI – ID 1067, SEBI Registration No. MSEI CDS Segment INZ000202536, Member MCX – ID 56460, SEBI Registration No. MCX COMMODITY Segment INZ000202536, Member NCDEX – ID 1268, SEBI Registration No. NCDEX COMMODITY Segment INZ000202536, Member ICEX – ID 2073, SEBI Registration No. ICEX COMMODITY Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CM Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE FO Segment INZ000202536, Member BSE – ID 0498, SEBI Registration No. BSE CDS Segment Exchange Registered Broker, Member BSE Commodity – ID 0498, SEBI Registration No. BSE COMMODITY Segment Exchange Registered Broker, SEBI Registration No. PMS INP000002981, SEBI Registration No. Research Analyst INP000002981, SEBI Registration No. DP Participants NSDL – CDSL IN-DP-CDSL 37-99,Member Comtrack Participant Id – ID 50274, Member NERL RP Id– ID R1447, Nirmal Bang Equities Private Limited Member BSE – ID 245, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. BSE CM Segment INZ000186135, Member NSE – ID 13437, SEBI Registration No. NSE FO Segment INZ000186135, Member NSE Currency – ID 13437, SEBI Registration No. NSE CDS Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI CM Segment INZ000186135, Member MSEI – ID 17780, SEBI Registration No. MSEI FO Segment INZ000186135, SEBI Registration No. Research Analyst Segment INH000001436, Nirmal Bang Commodities Private Limited Member MCX – ID 16590, SEBI Registration No. MCX COMMODITY Segment INZ000043630, Member NCDEX – ID 00362, SEBI Registration No. NCDEX COMMODITY Segment INZ000043630, Member ICEX – ID 1165, SEBI Registration No. ICEX COMMODITY Segment INZ000043630, Member NCDEX Spot Exchange – ID 10084,Comtrack Participant CPID -5040, Participant CDSL Commodity Repository Limited - 12013300
For any grievances, please get in touch on 022-62739390 and write a mail to Contact@nirmalbang.com with Subject line as Grievances/Complain.     |    

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

AppleApp Store GooglePlay Store
AppleApp StoreGooglePlay Store
Support
Videos
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.